Sanofi (NASDAQ:SNY – Get Rating)’s share price rose 0.6% during trading on Thursday . The company traded as high as $49.26 and last traded at $49.26. Approximately 28,872 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 2,119,409 shares. The stock had previously closed at $48.99.
SNY has been the topic of a number of analyst reports. Guggenheim lifted their price target on Sanofi from €121.00 ($126.04) to €127.00 ($132.29) in a research note on Monday, May 2nd. Barclays boosted their target price on Sanofi from €90.00 ($93.75) to €105.00 ($109.38) in a research note on Thursday, April 14th. Morgan Stanley boosted their target price on Sanofi from €110.00 ($114.58) to €112.00 ($116.67) in a research note on Friday, April 22nd. UBS Group boosted their target price on Sanofi from €118.00 ($122.92) to €119.00 ($123.96) and gave the company a “buy” rating in a research note on Tuesday, June 7th. Finally, Stifel Nicolaus assumed coverage on Sanofi in a research note on Monday, February 28th. They set a “buy” rating on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $108.83.
The company has a market capitalization of $123.36 billion, a PE ratio of 15.95, a PEG ratio of 1.24 and a beta of 0.49. The company has a 50 day moving average of $53.61 and a two-hundred day moving average of $51.89. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.44 and a quick ratio of 1.03.
The company also recently declared an annual dividend, which was paid on Wednesday, June 8th. Investors of record on Thursday, May 5th were paid a $1.7968 dividend. The ex-dividend date of this dividend was Wednesday, May 4th. This represents a yield of 2.7%. Sanofi’s payout ratio is 40.78%.
Institutional investors have recently added to or reduced their stakes in the business. GHP Investment Advisors Inc. bought a new stake in Sanofi in the first quarter worth $26,000. Fairfield Bush & CO. bought a new stake in Sanofi in the first quarter worth $26,000. First Community Trust NA bought a new position in shares of Sanofi during the fourth quarter valued at $26,000. Pinnacle Bancorp Inc. lifted its holdings in shares of Sanofi by 49.0% during the first quarter. Pinnacle Bancorp Inc. now owns 587 shares of the company’s stock valued at $30,000 after purchasing an additional 193 shares in the last quarter. Finally, Ahrens Investment Partners LLC bought a new position in shares of Sanofi during the first quarter valued at $31,000. 12.82% of the stock is currently owned by institutional investors and hedge funds.
About Sanofi (NASDAQ:SNY)
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- The Q2 Earnings Season Could Be A Bloodbath
- The Institutions Turn The Tide For Jabil
- Commercial Metals Company Is Ready To Rebound
- A10 Networks: Key 5G Infrastructure Stock that’s Beating the Market
- Allstate: A Safe Stock During Volatile Times, Which Will Benefit From Rising Rates
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.